Directly reprogrammed natural killer cells for cancer immunotherapy

Cited 24 time in scopus
Metadata Downloads

Full metadata record

DC FieldValueLanguage
dc.contributor.authorHan-Seop Kim-
dc.contributor.authorJae Yun Kim-
dc.contributor.authorBinna Seol-
dc.contributor.authorCho-Lok Song-
dc.contributor.authorJi Eun Jeong-
dc.contributor.authorYee Sook Cho-
dc.date.accessioned2021-11-18T15:30:54Z-
dc.date.available2021-11-18T15:30:54Z-
dc.date.issued2021-
dc.identifier.issn2157-846X-
dc.identifier.urihttps://oak.kribb.re.kr/handle/201005/25018-
dc.description.abstractEfficacious and accessible sources of natural killer (NK) cells would widen their use as immunotherapeutics, particularly for solid cancers. Here, we show that human somatic cells can be directly reprogrammed into NK cells with a CD56brightCD16bright phenotype using pluripotency transcription factors and an optimized reprogramming medium. The directly reprogrammed NK cells have strong innate-adaptive immunomodulatory activity and are highly potent against a wide range of cancer cells, including difficult-to-treat solid cancers and cancer stem cells. Both directly reprogrammed NK cells bearing a cancer-specific chimeric antigen receptor and reprogrammed NK cells in combination with antibodies competent for antibody-dependent cell-mediated cytotoxicity led to selective anticancer effects with augmented potency. The direct reprogramming of human somatic cells into NK cells is amenable to the production of autologous and allogeneic NK cells, and will facilitate the design and testing of cancer immunotherapies and combination therapies.-
dc.publisherSpringer-Nature Pub Group-
dc.titleDirectly reprogrammed natural killer cells for cancer immunotherapy-
dc.title.alternativeDirectly reprogrammed natural killer cells for cancer immunotherapy-
dc.typeArticle-
dc.citation.titleNature Biomedical Engineering-
dc.citation.number11-
dc.citation.endPage1376-
dc.citation.startPage1360-
dc.citation.volume5-
dc.contributor.affiliatedAuthorHan-Seop Kim-
dc.contributor.affiliatedAuthorJae Yun Kim-
dc.contributor.affiliatedAuthorBinna Seol-
dc.contributor.affiliatedAuthorCho-Lok Song-
dc.contributor.affiliatedAuthorJi Eun Jeong-
dc.contributor.affiliatedAuthorYee Sook Cho-
dc.contributor.alternativeName김한섭-
dc.contributor.alternativeName김재윤-
dc.contributor.alternativeName설빛나-
dc.contributor.alternativeName송초록-
dc.contributor.alternativeName정지은-
dc.contributor.alternativeName조이숙-
dc.identifier.bibliographicCitationNature Biomedical Engineering, vol. 5, no. 11, pp. 1360-1376-
dc.identifier.doi10.1038/s41551-021-00768-z-
dc.description.journalClassY-
Appears in Collections:
Division of A.I. & Biomedical Research > Immunotherapy Research Center > 1. Journal Articles
Files in This Item:
  • There are no files associated with this item.


Items in OpenAccess@KRIBB are protected by copyright, with all rights reserved, unless otherwise indicated.